The CJC-1295 + Ipamorelin combination is a common tool in growth-hormone research because it activates two complementary signaling routes to the pituitary.
Two pathways, one probe
CJC-1295 acts as a GHRH analog while Ipamorelin engages the ghrelin/GH-secretagogue receptor (see mechanism of action), letting researchers study additive or synergistic GH-release signaling.
Model systems
Pituitary cell cultures and preclinical models are used to read out GH-axis markers at defined in-vitro concentrations — set by assay design, not human dosing. Supporting evidence is summarized in preclinical research.
Why the pairing
The rationale for combining a selective agonist like Ipamorelin with a GHRH analog is discussed in CJC-1295 vs. Ipamorelin and their discovery history.
Product page: CJC-1295 & Ipamorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.